Introduction {#sec1}
============

The cost of medicine in the United States and abroad is increasing at an exponential and economically unsustainable rate. Technological advances leading to more expensive diagnostic and therapeutic tools have contributed to this increase, which in turn has led to rising pressure to demonstrate the value of such interventions. This has ultimately led to growing governmental, professional, organizational, and academic interests in the value propositions in the healthcare system. Cost-effectiveness analysis (CEA) is the primary modality by which investigators assess the value of an intervention. CEA evaluates the price of an intervention, either to the payer or to society, for an individual measure of effectiveness of that intervention.[@bib1] This can include the years of life added and quality of life added, among others.

A subset of cost-effectiveness analysis is cost-utility analysis (CUAs), which expresses the effectiveness of an intervention using a uniform unit of cost per quality adjusted life year (QALY). The QALY describes the time spent in a certain health state, multiplied by the quality of each state (with 1 QALY being perfectly healthy for one year).[@bib2] In this way, both a treatment that improves health related quality of life from 0.5 to 1.0 for 5 years and a treatment that leads to 5 additional years of life with a health condition of 0.5 both yield 2.5 QALYs. One general way to look at value is to assess the cost of an intervention and to correlate this with the benefits rendered, either in life gained or in quality of life improved. In cost-utility analysis, interventions are considered of favorable value if their cost is less than \$50,000 (USD) per QALY gained. As the cost per QALY decreases, the intervention becomes more cost effective. When comparing two interventions with the same intended goal, the intervention with the lower cost per QALY is the more economic choice.

Within all aspects of medical literature, there are an increasing number of studies evaluating cost utility. However, this is challenging within subspecialties such as otolaryngology due to a limited number of investigators and conditions compared to other specialties. Nevertheless, because otolaryngology utilizes costly diagnostic and therapeutic strategies for managing conditions such as head and neck cancer, hearing loss, and chronic sinusitis, it provides a fertile landscape for the assessment of cost effectiveness. The objectives of this study are to detail specific characteristics of CUAs within otolaryngology, to evaluate the quality of these studies and to summarize the collective results of the most common topics of economic evaluations in otolaryngology.

Methods {#sec2}
=======

We performed a quantitative and qualitative assessment of studies within the spectrum of otolaryngology between 1976 and 2011 using the CEA registry.[@bib3] The CEA registry is a database updated three times per year with publically available data on all publications that are published in English, are original cost-effectiveness analyses, and measure health benefits of QALYs. The CEA registry is supported by the Center for the Evaluation of Value and Risk in Health (CEVR) and is part of the Institute for Clinical Research and Health Policy Studies at Tufts Medical Center. The total number of studies available in the registry at the time of analysis was 2913. The registry\'s rigorous methodology for screening cost utility analysis manuscripts is described on the website. In short, a MEDLINE search is performed with the keywords, "QALYs" "quality," and "cost-utility analysis." The CEA registry team screens abstracts to assess if there is an original cost-utility estimate. Each article is then abstracted for methodology, cost-effectiveness ratios, and utility weights. Two trained readers audit each article independently and a consensus audit resolves discrepancies.

Author MAC systematically reviewed all of the articles within the CEA registry and screened for publications that fall within the field of otolaryngology, which includes head and neck surgery, endocrine surgery, otology, pediatric otolaryngology, rhinology, allergy and sleep medicine. The presence of an otolaryngologist author, as determined per affiliations listed on the manuscript, was not a factor in inclusion. In the unique case that affiliations were not named, an Internet search was conducted. Study characteristics, including year of publication, journal of publication, author affiliation, country of research, type of funding, analysis perspective, intervention type, and CEA registry quality score (numbered from 1 (low) to 7 (high) by expert readers). The criteria used to determine the CEA registry quality score of each study includes: 1. accurate computation of incremental cost-effectiveness ratios, 2. comprehensive characterization of the uncertainty of results, 3. explicit specification of health economic assumptions used in the study, and 4. appropriate and explicit estimation of utility weights ([Table 1](#tbl1){ref-type="table"}). The strength and direction of association between characteristics of each study and CEA registry quality scores were measured using the Pearson product moment correlation coefficient using the Statistical Package for Social Sciences (SPSS Version 22.0, Chicago, IL). The collective results of CUAs of the most commonly evaluated interventions were also assessed in order to identify economically attractive management options within otolaryngology.Table 1CEA registry quality score criteria, adapted from the Tufts CEA Registry.[@bib3]CEA registry quality score criteria (in order of importance)1Did the study authors correctly compute the incremental cost-effectiveness ratios?2Did the authors comprehensively characterize the uncertainty of the results?3Were the health economic assumptions used in the study (discount rate, currency, time horizon) explicitly specified?4Was there an appropriate and explicit estimation of utility weights?

Results {#sec3}
=======

Assessment of 2913 studies revealed 61CUAs that evaluated interventions related to otolaryngology. The earliest study was published in 1991 and assessed the cost-effectiveness of tympanostomy tubes versus antibiotic prophylaxis for acute otitis media (AOM). Eighty-five percent (52 of 61) of studies were published later than 2000, with 28 (45.9%) published between 2008 and 2011 ([Fig. 1](#fig1){ref-type="fig"}). The 61 publications addressed topics within the subspecialties of otology (31.1%), endocrine surgery (19.6%), sleep medicine/surgery (18.0%), head and neck surgery (13.0%), pediatric otolaryngology (8.2%), allergy (6.6%), and rhinology (3.3%) ([Fig. 2](#fig2){ref-type="fig"}). Of the 61 manuscripts related to otolaryngology, 18 (29.5%) studies had at least one author who was an otolaryngologist. Eight (13.0%) manuscripts had a first author and seven (11.4%) had a final author primarily affiliated with a department of otolaryngology. Seventy-two percent of publications with an otolaryngologist as a first author were related to otology.Fig. 1CUA publications per time period.Fig. 2Publication subspecialties.

The otolaryngology CUAs were published in 41 journals, with only five journals having three or more manuscripts ([Table 2](#tbl2){ref-type="table"}). Thirty-two (52.4%) economic analyses had the United States as the country of interest. Eight studies focused on the United Kingdom and five on Canada. Ninety-eight percent of manuscripts had at least one author with an academic affiliation. Seventy-one percent of analyses had the perspective of healthcare payer. The funding sources of the manuscripts were stated as none or could not be determined in 29 (47.5%), government funding in 17 (27.9%), pharmaceutical or device in 14 (22.9%), foundation in 6 (9.8%) and healthcare organization in 3 (4.9%) ([Table 2](#tbl2){ref-type="table"}). Two studies (3.3%) evaluated primary prevention strategies, which are defined as efforts to prevent disease prior to its occurrence. One of these primary prevention strategies analyzed oral cancer screening programs for high-risk males[@bib4] and the second evaluated candidate vaccines for prevention of pediatric acute otitis media.[@bib5] Thirteen studies assessed secondary prevention interventions (methods that identify and treat asymptomatic individuals with risk factors or preclinical disease) and 46 (75.4%) evaluated tertiary prevention interventions (methods that limit disability after harm has occurred). A majority of the studies evaluated the cost utility of devices (47.5%) or pharmaceuticals (29.5%) ([Table 2](#tbl2){ref-type="table"}).Table 2Demographic characteristics of CUAs.Study characteristicNo. Studies (%)Mean CEA registry quality score (range)**Subspecialty** Otology19 (31.1)3.8 (1.5--6.0) Endocrine surgery12 (19.7)4.2 (3.5--5.5) Sleep medicine/surgery11 (18.0)4.2 (2.5--6.0) Head and neck surgery8 (13.0)3.4 (2.5--5.0) Pediatric otolaryngology5 (8.2)4.3 (3.0--5.5) Allergy4 (6.6)4.5 (3.5--6.0) Rhinology2 (3.3)4.5 (4.0--5.0)**Journal (2011 impact factor)** Laryngoscope (1.752)6 (9.8)3.3 (1.5--4.5) Arch of Otolaryngology Head Neck Surg (1.63)4 (6.6)4.1 (1.5--5.0) Ear Hearing (2.578)3 (4.9)4.5 (3.0--6.0) Sleep (5.051)3 (4.9)4.2 (2.5--5.0) Value Health (2.191)3 (4.9)5.0 (4.0--6.0) Others36 (59)4.1 (1.5--6.0)Total No. of Journals414.0 (1.5--6.0)**Year of publication** 1976--19911 (1.6)3.0 1992--19954 (6.6)2.1 (1.5--3.0) 1996--19994 (6.6)3.9 (2--5.5) 2000--200310 (16.4)3.9 (1.5--5.5) 2004--200714 (22.9)4.0 (3.0--6.0) 2008--201128 (45.9)4.4 (2.5--6.0)**Country of analysis** United States32 (52.4)3.9 (1.5--6.0) United Kingdom8 (13.1)4.7 (1.5--6.0) Canada5 (8.2)4.1 (2.5--5.5) Australia3 (4.9)3.3 (3.0--4.0) Germany3 (4.9)4.2 (4.0--4.5) France2 (3.3)4.5 (3.5--5.5) Netherlands2 (3.3)3.5 (2.0--5.0) New Zealand1 (1.6)4.0 Austria1 (1.6)3.5 China1 (1.6)3.0 Finland1 (1.6)3.0 Belgium1 (1.6)5.0 Taiwan1 (1.6)5.0**Funding source** Government17 (27.9)4.1 (1.5--6.0) Pharmaceutical or device14 (22.9)3.8 (1.5--5.5) Could not be determined29 (47.5)3.9 (1.5--6.0) Foundation6 (9.8)4.3 (3.0--5.5) Healthcare organization3 (4.9)3.5 (1.5--4.5)**Perspective of study** Healthcare payer43 (70.5)3.9 (1.5--6.0) Societal17 (27.9)4.4 (3.0--5.5) Could not be determined1 (1.6)1.5**Intervention type** Primary2 (3.3)4.8 (4.0--5.5) Secondary13 (21.3)3.8 (2.0--6.0) Tertiary46 (75.4)4.0 (1.5--6.0)**Authors affiliation** Academic60 (98.4)4.0 (1.5--6.0) Consultant7 (11.5)4.4 (3.5--5.0) Government1 (1.6)3.0**Intervention assessed** Device29 (47.5)3.8 (1.5--6.0) Diagnostic6 (9.8)4.0 (3.0--5.0) Screening6 (9.8)3.4 (2.0--5.0) Health education1 (1.6)4.0 Medical procedure9 (14.7)4.1 (3.0--5.0) Pharmaceutical18 (29.5)4.6 (3.5--6.0) Surgical12 (19.7)3.9 (2.5--5.5) Immunization2 (3.3)5.0 (4.5--5.5) Care delivery2 (3.3)3.3 (3.0--3.5)

The mean CEA registry quality score (on a scale of 1--7) for all 61 studies was 4.00. A more recent publication year was associated with a higher CEA registry quality score (*r* = 0.412, *P* \< 0.01) ([Table 3](#tbl3){ref-type="table"}). The mean quality score for studies with at least one otolaryngology author was 3.77 and 4.09 for those without an otolaryngology author. There was no significant correlation between the number of otolaryngologist authors and the CEA quality score. The impact factor of the journal in which each study was published also had no significant association with the quality of the CUA. The references and topics for all 61 studies that relate to otolaryngology in the CEA database are listed in [Table 4](#tbl4){ref-type="table"}. Fourteen studies agreed on the cost-effectiveness of at least unilateral cochlear implantation and 6 of 7 studies demonstrated CPAP to be a cost-effective strategy for treating patients with OSA.Table 3Correlations between CUA characteristics and CEA registry quality score.VariableCorrelation coefficient, *rP* value\# of Otolaryngology authors−0.0430.749Publication year0.4120.001[a](#tbl3fna){ref-type="table-fn"}Journal impact factor0.1840.160[^1]Table 4Summary of evaluated CUAs.YearSpecialtyJournalReferenceTopic of CUA publication1991GeneralFam Pract Res JBisonni et al[@bib9]Tympanostomy tubes vs antibiotic prophylaxis for AOM1994SleepSleepTousignant et al[@bib10]Impact of nasal CPAP on quality of life for OSA1995OtologyAnn Otol Rhinol Laryngol SupplEvans et al[@bib11]Adult unilateral cochlear implant1995OtologyMed Prog TechnolLea et al[@bib12]Cochlear implantation vs vibrotactile devices1995OtologyArch Otolaryngol Head Neck SurgHarris et al[@bib13]Cochlear implantation for profound deafness1996OtologyLaryngoscopeWyatt et al[@bib14]Multichannel cochlear implants1996PediatricsClin TherOh et al[@bib15]Second-line antibiotics for pediatric AOM1999OtologyInt J Technol Assess Health CareCarter et al[@bib16]Pediatric and adult cochlear implantation1999OtologyArch Otolaryngol Head Neck SurgPalmer et al[@bib17]Adult cochlear implantation2000OtologyLaryngoscopeO\'Neill et al[@bib18]Pediatric cochlear implantation2000OtologyJAMACheng et al[@bib19]Pediatric cochlear implantation2001Head and neckCancerHollenbeak et al[@bib20]FDG-PET for N0 HNSCC2002EndocrineEur J EndocrinolVidal-Trecan et al[@bib21]Management of toxic thyroid adenomas2002OtologyOtol NeurotolBichey et al[@bib22]Cochlear implantation for large vestibular aqueduct syndrome2002OtologyLaryngoscopeFrancis et al[@bib23]Cochlear implantation in older adults2002Head and neckCommunity Dent Oral EpidemiolVan der Meij et al[@bib24]Cancer screening of patients with oral lichen planus2002OtologyArch Otolaryngol Head Neck SurgSummerfield et al[@bib25]Unilateral vs bilateral cochlear implantation2003OtologyArch Otolaryngol Head Neck SurgJoore et al[@bib26]Fitting of hearing aids2003OtologyLaryngoscopeWilson et al[@bib27]Intraoperative facial nerve monitoring for otologic surgery2004OtologyEar HearGroup, UKCIS et al[@bib28]Unilateral cochlear implantation in postlingually deafened adults2004EndocrineThyroidVidal-Trecan et al[@bib29]Radioiodine vs surgery for toxic thyroid adenoma2005EndocrineEur J EndocrinolSejean et al[@bib30]Surgery vs medical follow-up for primary hyperparathyroidism2005EndocrineANZ J SurgBlamey et al[@bib31]Recombinant human TSH for diagnosis of recurrent thyroid cancer2005SleepStrokeBrown et al[@bib32]Sleep study screening of stroke victims for OSA2006PediatricsPediatricsVan Howe et al[@bib33]Observation without testing for pediatric pharyngitis2006SleepArch Int MedAyas et al[@bib34]CPAP for moderate to severe OSA2006OtologyEar HearBarton et al[@bib35]Pediatric cochlear implantation2006EndocrineSurgeryZanocco et al[@bib36]Management of asymptomatic primary hyperparathyroidism2007PediatricsAnn Fam MedCoco et al[@bib37]Management of pediatric acute otitis media2007EndocrineAm J Kidney DisNarayan et al[@bib38]Parathyroidectomy vs cinacalcet for hyperparathyroidism in ESRD2007AllergyCurr Med Res OpinKeiding et al[@bib39]Immunotherapy for seasonal allergic rhinoconjunctivitis2007RhinologyAm J RhinolAnzai et al[@bib40]Management of acute sinusitis2007OtologyGenet MedVeenstra et al[@bib41]Testing for mitochondrial mutation (A155G) in cystic fibrosis2008SleepJ Int Med ResLojander et al[@bib42]Nasal CPAP for OSA2008OtologyOtol NeurotolChang et al[@bib43]Hearing aid outcome in the elderly2008AllergyAnn Allergy Asthma ImmunolBruggenjurgen et al[@bib44]Subcutaneous immunotherapy for allergic rhinitis and allergic asthma2008Head and neckValue HealthBrown et al[@bib45]Cetuximab plus radiotherapy for head and neck cancer2008SleepThoraxGuest et al[@bib46]CPAP for OSA2008SleepCan Respir JTan et al[@bib47]CPAP for OSA2008EndocrineSurgeryZanocco et al[@bib48]Parathyroidectomy vs observation for primary hyperparathyroidism2009EndocrineValue HealthMernagh et al[@bib49]Recombinant human TSH before RAI ablation for thyroid cancer2009Head and neckAnn OncolSher et al[@bib50]CT and PET-CT for determining need for neck dissection in HNSCC2009Head and neckDermatol SurgSeidler et al[@bib51]Mohs vs traditional surgery for nonmelanoma skin cancer2009RhinologyAppl Health Encon Health PolicyKneis et al[@bib52]Sinfrontal, homeopathic medication, for acute maxillary sinusitis2009Head and neckAcad RadiolYen et al[@bib53]MRI vs PET vs MRI-PET for diagnosis of recurrent NPC2009SleepInt J Technol Assess Health CareWeatherly et al[@bib54]CPAP vs dental devices and lifestyle advice for OSA2009AllergyAm J EpidemiolWitt et al[@bib55]Acupuncture for allergic rhinitis2009SleepSleep BreathSadatsafavi et al[@bib56]CPAP vs oral appliances for OSAH2009OtologyFam PractHernandez et al[@bib57]Management of Bell\'s palsy2009PediatricsPediatricsO\'Brien et al[@bib5]Candidate vaccines for prevention of pediatric AOM2009SleepSleepSnedecor et al[@bib58]Eszopiclone for primary chronic insomnia2009EndocrineJ Am Coll SurgIn et al[@bib59]Treatment options for Graves disease2010EndocrineAnn Surg OncolWang et al[@bib60]Oral calcium and calcitriol following total thyroidectomy2010OtologyEar HearSummerfield et al[@bib61]Bilateral pediatric cochlear implantation2010EndocrineJCEMWang et al[@bib60]Recombinant TSH prior to RAI for thyroid cancer2010AllergyValue HealthPetrou et al[@bib62]Topical intranasal steroids for pediatric OME2011SleepSleepPietzsch et al[@bib63]Diagnostic and therapeutic strategies for OSA2011SleepCost Eff Resour AllocScott et al[@bib64]Treatment of insomnia2011EndocrineJCEMLi et al[@bib65]Novel molecular test for indeterminate thyroid nodules2011Head and neckLaryngoscopeHiggins et al[@bib66]Radiation vs transoral laser surgery for early-stage glottic carcinoma2011Head and neckLaryngoscopeDedhia et al[@bib4]Oral cancer screening programs for high-risk males[^2]

Discussion {#sec4}
==========

In an effort to limit healthcare expenditures and to allocate resources efficiently, many groups have focused their work on the economic appraisal of clinical interventions. As healthcare costs rise, it remains unclear how the increasing economic burden will be handled. There is an increasing need for policy makers, administrators, and physicians alike to evaluate the cost-effectiveness of the services provided. Assessment of value has been investigated for decades, with an exponential increase in cost effectiveness analyses published in the past 10 years. Cost effectiveness research in otolaryngology may have an especially profound impact on limiting healthcare expenditures, as otolaryngologists manage many conditions associated with high costs. The cost of allergic rhinitis alone has been estimated to be close to 5.3 billions dollars per year in the United States.[@bib6] Interestingly, these costs are far surpassed by that of managing sinusitis, which impacts one in seven adults and has direct costs alone estimated at 5.8 billion dollars per year.[@bib7] Within otolaryngology, the management of head and neck cancer and thyroid disease is also especially costly, with only a portion of the costs reflected in direct expenditures of imaging, surgery, and radiation therapy. As healthcare costs continue to rise, it is vital that otolaryngologists take on a more active role in assessing the cost effectiveness of various management options as more expensive innovative technologies continue to be developed.

We have evaluated the CEA registry to assess the characteristics, results and quality of CUAs, which include only those studies measuring health benefits in QALYs, in otolaryngology. Despite the high cost of managing conditions in the practice of otolaryngology, only 2% of the total CUA literature in the CEA registry evaluates intervention sutilized by otolaryngologists and only 0.61% of the cost utility literature in the CEA registry included an otolaryngologist as an author. The relative paucity of otolaryngologists with published studies in the CEA registry may be related to a relative infrequency of conditions with well-established QALYs, fewer clinicians in otolaryngology with training to perform these investigations, or perhaps decreased awareness of these issues among otolaryngologists. Regardless of the reason, it is important that otolaryngologists become more involved in conducting these studies in order to actively participate in discussions regarding the allocation of heath care resources.

In a recent review assessing the quality of 50 economic evaluations published in otolaryngology, Liu and colleagues found that study characteristics such as journal impact factor and presence of an author with a PhD in health economics were associated with higher quality studies.[@bib8] Interestingly, in our study, the subjective quality score bestowed by the CEA registry revealed no statistically significant correlation between the quality of the manuscripts and the number of otolaryngologist authors or the impact factor of the journal in which the study was published. Our review did reveal that studies with a more recent publication year are associated with a higher quality score, indicating that despite the relative lack of CUAs related to otolaryngology, the studies have been improving in both quantity and quality in recent years. Assessment of the topics addressed by all of the studies and their collective results revealed that unilateral cochlear implantation is cost effective in all settings evaluated. Furthermore, 86% of studies identified CPAP to be a cost effective strategy for the management of OSA ([Table 3](#tbl3){ref-type="table"}).

Although the relatively large number of studies evaluated and the use of the CEA registry make this review unique, there are several limitations. The CEA registry is a limited database with regards to cost effectiveness literature as a whole. It is possible that many other cost-effectiveness analyses related to otolaryngology that do not adhere to the stringent CUA criteria, yet have made important contributions to understanding the cost of interventions in otolaryngology, have not been evaluated in this particular study. We did not perform our own manual search of all English literature to ensure that no publications were missing from the CEA registry, nor did we perform our own assessment of the individual studies included in this study. Despite this, we are the first group to perform a review of the CUA literature in otolaryngology that has fit the inclusion criteria of the CEA registry. Future reviews of CUAs in otolaryngology may wish to combine search results from multiple databases in order to more comprehensively review the literature in this field.

Conclusion {#sec5}
==========

Based on current evidence in the CEA registry, there is consensus that unilateral cochlear implantation for hearing loss and near consensus that CPAP for OSA are both cost effective interventions. Although CUAs in otolaryngology have increased in quantity and quality in more recent years, there is a lack of CUAs evaluating interventions in otolaryngology. A significant need exists for more otolaryngologists to become involved in evaluating the cost effectiveness of the therapeutic interventions they utilize.
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[^1]: Statistically significant.

[^2]: **Abbreviations:** AOM, acute otitis media; PAP, continuous positive airway pressure; T, computed tomography; CUA, cost-utility analysis; ESRD, end stage renal disease; FDG-PET, 18-F fluoro-2-deoxyglucose positron emission tomography; HNSCC, head and neck squamous cell carcinoma; MRI, magnetic resonance imaging; NPC, nasopharyngeal carcinoma; OME, otitis media with effusion; OSA, obstructive sleep apnea; OSAH, obstructive sleep apnea-hypopnea; PET-CT, positron emission tomography-computed tomography; TSH, thyroid stimulating hormone; RAI, radioiodine.
